Candesartan CAS 139481-59-7 Maʻemaʻe >99.0% (HPLC) Hale Hana
ʻO Ruifu Chemical Supply Candesartan Cilexetil Intermediate Me ka Maʻemaʻe Kiʻekiʻe
Candesartan Cilexetil CAS 145040-37-5
Candesartan CAS 139481-59-7
1-Chloroethyl Cyclohexyl Carbonate CAS 99464-83-2
Candesartan Cilexetil Intermediate Eethyl Ester C6 CAS 139481-41-7
Candesartan Cilexetil Intermediate CAS 139481-44-0
Trityl Candesartan Cilexetil CAS 170791-09-0
Inoa Kimia | Candesartan |
Nā huaʻōlelo like | CV-11974;2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-Carboxylic Acid;3-[[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid;Candesartan M1;Candesartan Cilexetil EP Impurity G |
Helu CAS | 139481-59-7 |
Helu CAT | RF-PI1889 |
Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
ʻĀpana Molekala | C24H20N6O3 |
Kaumaha Molecular | 440.45 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pauda keʻokeʻo |
ʻIkepili-HPLC | Ka Manawa Paʻa e like me ka maʻamau |
Identification-IR | E like me ka Standard |
Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) |
Lae hehee | 183.0~185.0 ℃ |
Nalo ma ka maloo | <0.50% |
Māmā (KF) | <0.50% |
Koena ma ka Ignition | <0.50% |
Nā Metala Kaumaha | <20ppm |
Ka haumia o ke kanaka | <1.00% (HPLC) |
Huina paumaele | <1.00% (HPLC) |
Hōʻike Hōʻike | n20/D 1.745~1.747 |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | API;No ka Lapaʻau ʻana i ke kiʻekiʻe |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO Candesartan (CAS: 139481-59-7) kahi ʻano antagonist receptor angiotensin II me IC50 o 0.26 nM.Target: ʻO ka Angiotensin II Receptor candesartan i hōʻike ʻia no ka mālama ʻana i ka hypertension.Ua ʻae mua ʻia ʻo Candesartan Cilexetil ma GB ma ʻApelila 29, 1997, a laila ʻae ʻia e ka US Food and Drug Administration (FDA) ma Iune 4, 1998, a apono ʻia e Pharmaceuticals and Medical Devices Agency of Japan (PMDA) ma Mar 12, 1999. Ua hoʻomohala ʻia e AstraZeneca, a laila kūʻai ʻia ʻo Atacand e AstraZeneca ma GB a me US, a kūʻai ʻia ʻo Blopress e Takeda ma JP.ʻO Candesartan Cilexetil kahi angiotensin II receptor blocker (ARB), e ālai i ka vasoconstrictor a me ka aldosterone-secreting hopena o ka angiotensin II ma ke koho ʻana i ka paʻa ʻana o ka angiotensin II i ka AT1 receptor i loko o nā ʻiʻo he nui, e like me ka vascular smooth muscle a me ka adrenal gland.Hōʻike ʻia ʻo Atacand no ka mālama ʻana i ke kiʻekiʻe kiʻekiʻe i nā pākeke a me nā keiki 1 a <17 mau makahiki o ka makahiki, ka puʻuwai puʻuwai (NYHA class II-IV) a hoʻohana ʻia e hōʻemi i ka make cardiovascular a me ka hoʻomaha ʻana i ka naʻau.